All In Biotech

BLA 125151 · Shire

Elaprase

Idursulfase · Iv (Infusion) · Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Nov 16, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jul 24, 2006

Approved uses

3

Original approval plus efficacy supplements

Registered trials

20

9 Phase 3, 1 recruiting

FAERS reports

3,986

3,520 serious, 684 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF ANAPHYLAXIS Life-threatening anaphylactic reactions have occurred in some patients during and up to 24 hours after ELAPRASE infusions. Anaphylaxis, presenting as respiratory distress, hypoxia, hypotension, urticaria and/or angioedema of throat or tongue have been reported to occur during and after ELAPRASE infusions, regardless of duration of the course of treatment. Closely observe patients during and after ELAPRASE administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions and require additional monitoring [see Warnings and Precautions (5.1 , 5.3) and Adverse Reactions...

What it is approved for

From the label in effect Apr 15, 2025.

ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older. The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age [see Use in Specific Populations (8.4) ]. ELAPRASE is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older. The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age ( 1 ).

Mechanism: Hunter syndrome (Mucopolysaccharidosis II, MPS II) is an X-linked recessive disease caused by insufficient levels of the lysosomal enzyme iduronate-2-sulfatase. This enzyme cleaves the terminal 2- O -sulfate moieties from the glycosaminoglycans (GAG) dermatan sulfate and heparan sulfate. Due to the missing or defective iduronate-2-sulfatase enzyme in patients with Hunter syndrome, GAG progressively accumulate in the lysosomes of a variety of cells, leading to cellular engorgement, organomegaly, tissue destruction, and organ system dysfunction. ELAPRASE is intended to provide exogenous enzyme...

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 24, 2013 Supplement 184 · Efficacy · priority review OrphanLabelLetter
  • Jun 24, 2013 Supplement 152 · Efficacy LabelLetter
  • Jul 24, 2006 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanReviewLetter
1 products under this application
  • ELAPRASE · IDURSULFASE 6MG/3ML · INJECTABLE, IV (INFUSION) · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Idursulfase" as an intervention, any sponsor and status, largest first.

All 20 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia618
  • product dose omission issue495
  • inappropriate schedule of product administration415
  • infusion related reaction389
  • cough312
  • pneumonia300
  • death271
  • dyspnoea262
  • influenza234
  • seizure217
  • covid-19207
  • malaise199

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200710
200843
200996
201078
201173
201294
2013230
2014191
2015281
2016201
2017189
2018275
2019253
2020267
2021661
2022336
2023284
2024163
2025137
2026124

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Elaprase (Idursulfase)

2024 spending

$7.0M

Beneficiaries

n/a

111 claims

Per beneficiary

n/a

$1,023.62 per unit

View as table
YearSpending
2020$4,521,568
2021$6,158,923
2022$6,796,718
2023$6,048,528
2024$6,970,861

Part B: Elaprase (Idursulfase) · HCPCS J1743

2024 spending

$3.4M

Beneficiaries

n/a

163 claims

Per beneficiary

n/a

2024 ASP limit $542.16 per unit

View as table
YearSpending
2020$952,367
2021$1,680,891
2022$1,800,137
2023$3,580,993
2024$3,382,670

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 34 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.